THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL

Christoph B. Olivier,Freddy Abnousi,Vandana Sundaram,Jaden Yang,Gregg W. Stone,Philippe Gabriel Steg,C. Michael Gibson,Christian W. Hamm,Matthew J. Price,Efthymios Deliargyris,Jayne Prats,Harvey D. White,Robert A. Harrington,Deepak L. Bhatt,Kenneth W. Mahaffey,Celina M. Yong,Champion Phoenix Investigators

THE EFFICACY AND SAFETY OF CANGRELOR FOR PATIENTS UNDERGOING SINGLE VESSEL VERSUS MULTI VESSEL PERCUTANEOUS CORONARY INTERVENTION: INSIGHTS FROM THE CHAMPION PHOENIX TRIAL

2018

Christoph B. Olivier
Freddy Abnousi
Vandana Sundaram
Jaden Yang
Gregg W. Stone
Philippe Gabriel Steg
C. Michael Gibson
Christian W. Hamm
Matthew J. Price
Efthymios Deliargyris
Jayne Prats
Harvey D. White
Robert A. Harrington
Deepak L. Bhatt
Kenneth W. Mahaffey
Celina M. Yong
Champion Phoenix Investigators

The intravenous, rapidly acting P2Y12 inhibitor cangrelor reduces the rate of ischemic events during percutaneous coronary intervention (PCI) with no significant increase in severe bleeding. This study aimed to evaluate the efficacy and safety of cangrelor in patients treated with single vessel (SV

Keywords:

Cangrelor
Champion
Percutaneous coronary intervention
Cardiology
Internal medicine
P2Y12
Medicine
severe bleeding
Conventional PCI
Diabetes mellitus
single vessel

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations